Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 CHRNA4 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D08669 Varenicline [3] 6, 18, 53
2 CHRNB2 [4] Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D08669 Varenicline [3] 6, 18, 53
3 CSF3R [5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03247 Lenograstim [7] 2, 13, 16, 18, 19, 57, 65
4 MTOR [5] Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia D00753 Sirolimus [40] 2, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331
5 MTOR [5] Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia D02714 Everolimus [9] 34, 67, 89, 96, 137, 157, 158, 228, 277
6 MTOR [5] Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia D06068 Temsirolimus [1] 13
7 GABBR1 [7] cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D00241 Baclofen [8] 2, 10, 13, 18, 65, 70, 149, 206
8 GABRA1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
9 GABRA2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
10 GABRA3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
11 GABRA4 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
12 GABRA5 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
13 GABRA6 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
14 GABRB1 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
15 GABRB2 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
16 GABRB3 [6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
17 GABRD [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
18 GABRE [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
19 GABRG1 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
20 GABRG2 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
21 GABRG3 [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
22 GABRP [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
23 GRIA1 [1] Spinocerebellar ataxia D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
24 GRIA1 [14] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
25 GRIA1 [1] Spinocerebellar ataxia D02696 Talampanel [2] 2, 6
26 GRIA1 [1] Spinocerebellar ataxia D08964 Perampanel [3] 2, 6, 144
27 GRIA2 [1] Spinocerebellar ataxia D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
28 GRIA2 [15] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
29 GRIA2 [1] Spinocerebellar ataxia D02696 Talampanel [2] 2, 6
30 GRIA2 [1] Spinocerebellar ataxia D08964 Perampanel [3] 2, 6, 144
31 GRIA3 [2] Spinocerebellar ataxia, Transcriptional misregulation in cancer D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
32 GRIA3 [13] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
33 GRIA3 [2] Spinocerebellar ataxia, Transcriptional misregulation in cancer D02696 Talampanel [2] 2, 6
34 GRIA3 [2] Spinocerebellar ataxia, Transcriptional misregulation in cancer D08964 Perampanel [3] 2, 6, 144
35 GRIA4 [10] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
36 GRIK1 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
37 GRIK2 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
38 GRIK3 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
39 GRIK4 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
40 GRIK5 [2] Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
41 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
42 GRIN1 [1] Spinocerebellar ataxia D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
43 GRIN1 [1] Spinocerebellar ataxia D07058 Acamprosate [2] 6, 206
44 GRIN1 [1] Spinocerebellar ataxia D07283 Esketamine [3] 2, 4, 70
45 GRIN1 [1] Spinocerebellar ataxia D07441 Amantadine [4] 6, 8, 13, 127
46 GRIN1 [1] Spinocerebellar ataxia D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
47 GRIN1 [1] Spinocerebellar ataxia D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
48 GRIN1 [1] Spinocerebellar ataxia D09917 Latrepirdine [1] 8
49 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
50 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
51 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
52 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
53 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
54 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
55 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
56 GRIN2A [2] Spinocerebellar ataxia, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
57 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
58 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
59 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
60 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
61 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
62 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
63 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
64 GRIN2B [2] Spinocerebellar ataxia, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
65 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
66 GRIN2C [1] Spinocerebellar ataxia D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
67 GRIN2C [1] Spinocerebellar ataxia D07058 Acamprosate [2] 6, 206
68 GRIN2C [1] Spinocerebellar ataxia D07283 Esketamine [3] 2, 4, 70
69 GRIN2C [1] Spinocerebellar ataxia D07441 Amantadine [4] 6, 8, 13, 127
70 GRIN2C [1] Spinocerebellar ataxia D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
71 GRIN2C [1] Spinocerebellar ataxia D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
72 GRIN2C [1] Spinocerebellar ataxia D09917 Latrepirdine [1] 8
73 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
74 GRIN2D [1] Spinocerebellar ataxia D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
75 GRIN2D [1] Spinocerebellar ataxia D07058 Acamprosate [2] 6, 206
76 GRIN2D [1] Spinocerebellar ataxia D07283 Esketamine [3] 2, 4, 70
77 GRIN2D [1] Spinocerebellar ataxia D07441 Amantadine [4] 6, 8, 13, 127
78 GRIN2D [1] Spinocerebellar ataxia D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
79 GRIN2D [1] Spinocerebellar ataxia D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
80 GRIN2D [1] Spinocerebellar ataxia D09917 Latrepirdine [1] 8
81 NR3C1 [1] Neuroactive ligand-receptor interaction D00407 Methylprednisolone [42] 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296
82 HMGCR [4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D08492 Rosuvastatin [11] 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299
83 IFNGR1 [18] Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
84 IFNGR2 [17] Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease D00747 Interferon gamma-1b [7] 18, 65, 85, 228, 299, 301, 326
85 KCNC3 [1] Spinocerebellar ataxia D04127 Dalfampridine [5] 3, 4, 6, 13, 14
86 KCNC3 [1] Spinocerebellar ataxia D10228 Amifampridine [3] 3, 11, 12
87 KCND3 [1] Spinocerebellar ataxia D02910 Amiodarone [2] 28, 127
88 KCND3 [1] Spinocerebellar ataxia D04127 Dalfampridine [5] 3, 4, 6, 13, 14
89 KCND3 [1] Spinocerebellar ataxia D10228 Amifampridine [3] 3, 11, 12
90 MAP3K5 [4] Tight junction, TNF signaling pathway, Thermogenesis, Spinocerebellar ataxia D10988 Selonsertib [1] 86
91 NFE2L2 [7] Protein processing in endoplasmic reticulum, Parkinson disease, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10964 Omaveloxolone [1] 18
92 PIK3CA [9] VEGF signaling pathway, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Yersinia infection, Viral carcinogenesis D11011 Alpelisib [1] 138
93 PIK3CA [9] VEGF signaling pathway, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Yersinia infection, Viral carcinogenesis D11158 Leniolisib [2] 53, 65
94 PIK3CB [9] VEGF signaling pathway, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Yersinia infection, Viral carcinogenesis D11158 Leniolisib [2] 53, 65
95 PIK3CD [9] VEGF signaling pathway, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Yersinia infection, Viral carcinogenesis D11158 Leniolisib [2] 53, 65
96 PIK3CD [9] VEGF signaling pathway, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Yersinia infection, Viral carcinogenesis D11437 Parsaclisib [3] 35, 53, 61
97 PRKCB [6] Vascular smooth muscle contraction, Wnt signaling pathway, VEGF signaling pathway, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Spinocerebellar ataxia D11935 Enzastaurin [1] 168
98 GABRQ [5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil [5] 6, 13, 17, 18, 206
99 PSMB5 [1] Spinocerebellar ataxia D03150 Bortezomib [17] 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 222, 228, 256, 283, 288, 331
100 PSMB5 [1] Spinocerebellar ataxia D08880 Carfilzomib [1] 28
101 PSMB5 [1] Spinocerebellar ataxia D10130 Ixazomib [5] 13, 16, 28, 51, 61
102 SLC6A2 [1] Synaptic vesicle cycle D07591 Bupropion [4] 18, 21, 96, 171
103 SLC6A3 [7] Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D07591 Bupropion [5] 8, 18, 21, 96, 171
104 SLC6A4 [2] Synaptic vesicle cycle, Serotonergic synapse D07704 Citalopram [7] 6, 8, 13, 18, 46, 98, 127
105 VDR [5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00129 Calcitriol [9] 18, 37, 46, 49, 66, 96, 158, 235, 326
106 GABBR2 [7] cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D00241 Baclofen [8] 2, 10, 13, 18, 65, 70, 149, 206